CANNES, FRANCE, April 12, 2014 (Press-News.org) According to the Alpes Maritimes' branch, FNAIM 06, the number of French Riviera property sales fell by 10% in 2013; the figure is an improvement on 2012 when sales in the region were down nearly 15%.
Drops in real estate prices have been seen across the French Riviera, the average price per square metre in Nice in the last quarter of 2013 was 4,134 euros compared to 4,293 euros in 2012.
Cannes and Antibes saw similar reductions with the average price in 2013 at 4,634 euros and 4,460 euros respectively per square metre.
Of course in the fashionable French Riviera there are always exceptions and some of the fashionable resorts on the coast reported a slight rise.
Philip Weiser of luxury property brokers Carlton International said that "the general economic situation in France together with the fiscal uncertainty, is responsible for the temporary decline in transactions and corresponding decline in prices."
The fall in demand for South of France property over recent years leading to lower prices is sure to give savvy investors untold opportunities, especially at the top end of the market. Weiser, who has over 30 years experience in luxury property investment said "these opportunities are rare in prime areas such as London, New York, Paris and the French Riviera. Historically, such opportunities occurred from 1982 to 1985, 1991 to 1994 and now, beginning in 2011."
He also urged investors to look at the market trends for these periods saying "historically, this period is not unlimited in time and the cycle will soon end. Now is the time to invest in the knowledge that values of properties bought at market value tend to double every ten years in normal times but inflate disproportionately after difficult times."
On the Cote d'Azur the limited capacity for additional construction has restricted the over-building seen in many parts of the world. Demand, both for primary and secondary residences has, more often than not, exceeded supply and this is a trend we are likely to see return.
Carlton International shared more good news for those seeking luxury property in the South of France; "The result in a weak market is that an owner wishing to sell within a given period is obliged to be competitive in terms of price. Furthermore, it is evident that homes which sell in these circumstances are generally better prepared for the market and in better condition."
The reticence of the banking institutions to lend to the French primary home market during awkward times can make it difficult to obtain a loan for French citizens. For non French investors, the banks are more adaptable, given the secondary home nature of the investments made by foreign buyers, who often have no need for financing, other than to offset any French Wealth Tax liability.
Despite the downturn in prices, there will always be property owners who need to sell due to a variety of circumstances, be it for work, financial or family commitments. This is all good news for those buyers who are new to the market in the South of France and in particular for foreign investors.
ABOUT CARLTON INTERNATIONAL
Carlton International is a prestigious real-estate agency based in the South of France. Our experienced consultants consistently negotiate French property transactions at the highest end of the market earning us a reputation as specialists in luxury French Riviera property sales and rentals. We offer a discreet service allowing our wealthy customers the privacy required for such transactions.
For those looking to purchase luxury property on the French Riviera, Carlton International can assist you in your search. Carlton International represents some of the most exclusive property for sale in the south of France. St. Tropez, Cap D'Antibes, Cap Ferrat and Cannes real estate are all available to be viewed through the website at www.carlton-international.com.
French Riviera Still a Buyer's Market According to New Figures
The number of real estate transactions taking place on the French Riviera continued to fall in 2013 leading to lower prices across much of the region.
2014-04-12
ELSE PRESS RELEASES FROM THIS DATE:
Extreme Weather Alert: Revolutionary New Dry Skin Cream Soars Above Accepted Industry Standard
2014-04-12
How well do dry skin care lotions fare against each other when tested for the ability to keep one's skin moisturized, especially during our constantly changing weather conditions? A new study, which included the shielding lotion Skin MD Natural had surprising results according to Germaine Muniz at Cantor Research Laboratories.
Cantor Research Laboratories discovered that when Skin MD Natural skin lotion treatment was applied to dry skin, it actually increased the skin's ability over time to retain moisture. All other products tested, including Vaseline Petroleum Jelly ...
Hepatitis C treatment cures over 90 percent of patients with cirrhosis
2014-04-12
SAN ANTONIO, Texas (April 12, 2014) — Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute. Historically, hepatitis C cure rates in patients with cirrhosis (liver scarring) have been lower than 50 percent and the treatment was not safe for many of these patients.
Hepatitis C virus is the No. 1 driver of cirrhosis, liver transplants ...
Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients
2014-04-12
London, UK, Saturday 12 April 2014: Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary composite endpoint ...
Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients
2014-04-12
London, UK, Saturday 12 April 2014: Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
"Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of Ankara, Turkey.
In the first study , CHB patients ...
New Chinese herbal medicine has significant potential in treating hepatitis C
2014-04-12
London, UK, Saturday 12 April 2014: Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.[i]
SBEL1 is a compound isolated from Chinese herbal medicines that was found to inhibit HCV activity by approximately 90%. SBEL1 is extracted from a herb found in certain regions of Taiwan and Southern China. In Chinese medicine, it is used to treat sore throats and inflammations. The function of SBEL1 ...
Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients
2014-04-12
London, UK, Saturday 12 April 2014: Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014.
"With cure rates well in excess of 90% with as little as eight weeks of treatment for some patients, these data represent ...
Gut microbiota may play a role in the development of alcoholic liver disease
2014-04-12
London, UK, Saturday 12 April 2014: Exciting new data presented today at the International Liver Congress™ 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).1 Though an early stage animal model, the French study highlights the possibility of preventing ALD with faecal microbiota transplantation – the engrafting of new microbiota, usually through administering human faecal material from a healthy donor into the colon of a recipient.2
In the study, two groups of germ-free mice received gut microbiota transplants ...
Low vitamin D linked to fatty liver disease in UK children
2014-04-12
London, UK, Saturday 12 April 2014: A UK study[i] investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity.
The research, conducted by the King's College Hospital Paediatric Liver Centre and the University of Surrey's School of Biosciences and Medicine, and funded by the Children's Liver Disease Foundation retrospectively analysed the medical records of 120 paediatric patients with NAFLD.
The findings could carry significant implications ...
New advances in HCC diagnosis, staging and treatment all predicted to improve patient outcomes
2014-04-12
London, UK, Saturday 12 April 2014: Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
"Human hepatocellular carcinoma is one of the most prevalent cancers worldwide and the second most frequent cause of cancer-related death," said EASL's Scientific Committee Member Dr Helen Reeves Senior Lecturer & Honorary Consultant Gastroenterologist at Newcastle Hospitals NHS Foundation Trust, ...
New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients
2014-04-12
London, UK, Saturday 12 April 2014: The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014.
The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase inhibitor ABT-333.
"Using this investigational ...
LAST 30 PRESS RELEASES:
Soccer heading damages brain regions affected in CTE
Autism and neural dynamic range: insights into slower, more detailed processing
AI can predict study results better than human experts
Brain stimulation effectiveness tied to learning ability, not age
Making a difference: Efficient water harvesting from air possible
World’s most common heart valve disease linked to insulin resistance in large national study
Study unravels another piece of the puzzle in how cancer cells may be targeted by the immune system
Long-sought structure of powerful anticancer natural product solved by integrated approach
World’s oldest lizard wins fossil fight
Simple secret to living a longer life
Same plant, different tactic: Habitat determines response to climate
Drinking plenty of water may actually be good for you
Men at high risk of cardiovascular disease face brain health decline 10 years earlier than women
Irregular sleep-wake cycle linked to heightened risk of major cardiovascular events
Depression can cause period pain, new study suggests
Wistar Institute scientists identify important factor in neural development
New imaging platform developed by Rice researchers revolutionizes 3D visualization of cellular structures
To catch financial rats, a better mousetrap
Mapping the world's climate danger zones
Emory heart team implants new blood-pumping device for first time in U.S.
Congenital heart defects caused by problems with placenta
Schlechter named Cancer Moonshot Scholar
Two-way water transfers can ensure reliability, save money for urban and agricultural users during drought in Western U.S., new study shows
New issue of advances in dental research explores the role of women in dental, clinical, and translational research
Team unlocks new insights on pulsar signals
Great apes visually track subject-object relationships like humans do
Recovery of testing for heart disease risk factors post-COVID remains patchy
Final data and undiscovered images from NASA’s NEOWISE
Nucleoporin93: A silent protector in vascular health
Can we avert the looming food crisis of climate change?
[Press-News.org] French Riviera Still a Buyer's Market According to New FiguresThe number of real estate transactions taking place on the French Riviera continued to fall in 2013 leading to lower prices across much of the region.